The Pilot-Line Problem: Why Britain's Materials Spinouts Stall Before the First Factory

Britain does not have a science problem. It has a plumbing problem.

The country's materials research base is genuinely formidable: the Henry Royce Institute's hub-and-spoke network, the formulation and printable-electronics capability at CPI in Sedgefield, composites at the National Composites Centre in Bristol, battery scale-up at UKBIC in Coventry. The output of papers, patents and doctoral talent remains disproportionate to the size of the economy. Yet the translation rate into tonnage-scale manufacturing is poor, and has been for two decades.

The reason is rarely a shortage of ideas. It is that the gap between a laboratory process running at grams per batch and a commercial line running at tonnes per year is a physical gap, not a financial abstraction. It has capital cost, floor space, utilities, permits, trained operators and – crucially – time. That gap is where most UK materials companies stop.

The valley of death is measured in metres, not millions

A cathode or solid-electrolyte chemistry that performs beautifully in a coin cell must survive coating, calendering, drying and formation at width. A graphene-enhanced composite that improves fracture toughness in a laminate coupon must survive autoclave cycles at the scale a tier-one supplier will actually run. A smart coating must survive a 1,000-hour salt-spray test and a customer's own qualification protocol before anyone signs a purchase order.

The equipment that bridges this – roll-to-roll coaters, dry rooms, continuous furnaces, extrusion lines, automated metrology – is expensive and, worse, underutilised by any single startup. A pilot line built for one chemistry is a stranded asset if that chemistry fails. Building it in-house is a bet most founders cannot finance at Series A, and cannot justify to a venture syndicate that wants capital deployed into commercial traction rather than into plant.

The result is a familiar stutter: a £2–5m seed round buys a prototype and a convincing data pack; the £15–30m required for a first meaningful line is precisely the round the UK is worst at supplying.

What the public toolkit covers – and where it stops

The UK's innovation infrastructure is better than its reputation suggests. The High Value Manufacturing Catapult's centres offer genuine scale-up capability, and UKBIC has become the default answer to the question of where a battery startup goes next. But these facilities were designed as demonstrators and capability-builders, not as permanently subsidised utilities. Access is priced, capacity is contested, and booking a slot is not the same as securing an offtake contract.

The softest spot is the middle: roughly technology readiness levels four to six, where a process must be proven continuously rather than in batches. Below that, universities and grant funding serve well. Above it, a plant exists or the company does not. In between, founders spend eighteen months assembling a consortium, a grant application and a lease.

Graphene remains the cautionary tale

Graphene was isolated at Manchester in 2004, and the National Graphene Institute opened in 2015 with substantial public backing. A decade on, the UK has deep intellectual property, a cluster of specialist firms and a strong reputation – but no graphene industry of the kind the original enthusiasm implied. That is not a failure of the science. It is a failure to match flagship buildings with flagship demand.

Graphene's most credible near-term markets – composites, barrier coatings, thermal management, sensors – are all served by industries that qualify materials slowly and suspiciously, and that buy on risk-adjusted total cost rather than on novelty. Qualifying a new material into an aerospace or automotive supply chain can consume two to four years of sampling and re-testing. No amount of seed capital compresses that clock.

Why the capital stack, not the cheque size, is the problem

The UK has spent a decade discussing patient capital without always being precise about what it means. For materials, patience is less about holding period than about structure. A ten-year fund still needs a company to survive years three to seven, and that requires revenue, not just runway.

Three mechanisms matter more than headline fund sizes. First, offtake-backed project finance: debt and equity raised against a signed customer contract rather than against a pitch deck. Second, staged capex: modular lines that add capacity in increments and can be relocated or repurposed. Third, royalty and revenue-share instruments that let a specialist manufacturer co-invest in a line without taking control of the company.

Domestic policy has been moving in this direction. The National Wealth Fund's mandate explicitly contemplates industrial decarbonisation and supply-chain investment; the British Business Bank's later-stage programmes have expanded; and the pension reforms begun at Mansion House in 2023 have started, slowly, to push defined-contribution schemes toward productive assets. Each helps at the margin. None yet amounts to a coherent answer to the missing middle.

The competitive pressure is real. US manufacturing tax credits and Department of Energy loan programmes, and the EU's Innovation Fund, offer scale-up capital on terms the UK does not currently match. Founders with a choice increasingly make it on the basis of where a line can be financed, not where the science was done.

The case for shared pilot lines

The most credible structural fix is a tolling model: publicly co-funded pilot facilities with published rate cards, open access, and priority booking for companies that hold equity in the facility. Semiconductor foundries proved the logic decades ago. Materials has equivalents already – CPI's formulation and printable-electronics lines, the Materials Innovation Factory's automation-led approach at Liverpool – but they are not yet knitted into a national offer with predictable pricing and commercial governance.

Such a model needs three things to work. Anchor demand from large corporates willing to pre-qualify materials on shared equipment. Governance that rewards utilisation rather than prestige. And investors who treat a pilot-line slot as an asset on the balance sheet rather than an overhead.

What diligence should ask in 2026

For investors, the questions have shifted. Who owns the line on which the next sample will be made? Is there a named first customer with a qualification timeline in writing? Does the business model survive if the pilot line becomes a public utility available to competitors? And, bluntly, is this a materials company or a manufacturing-services company wearing a materials company's clothes?

The next British deep-tech winner in materials will not be the team with the best paper. It will be the team that reached tonnage, on equipment it did not have to buy alone, for a customer that had already signed. Getting there requires patient capital – but above all it requires shared infrastructure and demand-led finance. Without those, the valley of death will keep claiming its casualties, and the most interesting chemistry will keep leaving the lab only in a suitcase.